Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Acceleron Pharma Inc.)"
Count: 33
Selected: 0
NCT IDTitle
NCT04948554Study of ACE-1334 to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Efficacy in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease
NCT04945460A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF
NCT04896008A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality
NCT04811092Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients
NCT04796337A Long-term Follow-up Study of Sotatercept for PAH Treatment
NCT04576988A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (STELLAR)
NCT03943290Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
NCT03738150A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
NCT03496207A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT03478319A Study of ACE-2494 in Healthy Subjects
NCT03124459Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
NCT02927080Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT02268409ACE-536 Extension Study - Beta Thalassemia
NCT02268383ACE-536 Extension Study - Myelodysplastic Syndromes
NCT02257489Phase 1 Study of ACE-083 in Healthy Subjects
NCT02024087Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
NCT01749540Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia
NCT01749514Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
NCT01727336Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT01458392Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT01432717Study of ACE-536 in Healthy Postmenopausal Women
NCT01239758Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
NCT01099761Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
NCT00996957Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
NCT00952887A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women
NCT00755638A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers
NCT00709540A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
NCT04143724Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants Who Require Regular RBC Transfusions Due to Beta (β)-Thalassemia.
NCT03682536Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions
NCT03342404A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
NCT02631070A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
NCT02604433An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
NCT01146574A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.